Mass spectrometric analysis of purine de novo biosynthesis intermediates. 2018

Lucie Mádrová, and Matyáš Krijt, and Veronika Barešová, and Jan Václavík, and David Friedecký, and Dana Dobešová, and Olga Součková, and Václava Škopová, and Tomáš Adam, and Marie Zikánová
Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, Czech Republic.

Purines are essential molecules for all forms of life. In addition to constituting a backbone of DNA and RNA, purines play roles in many metabolic pathways, such as energy utilization, regulation of enzyme activity, and cell signaling. The supply of purines is provided by two pathways: the salvage pathway and de novo synthesis. Although purine de novo synthesis (PDNS) activity varies during the cell cycle, this pathway represents an important source of purines, especially for rapidly dividing cells. A method for the detailed study of PDNS is lacking for analytical reasons (sensitivity) and because of the commercial unavailability of the compounds. The aim was to fully describe the mass spectrometric fragmentation behavior of newly synthesized PDNS-related metabolites and develop an analytical method. Except for four initial ribotide PDNS intermediates that preferentially lost water or phosphate or cleaved the forming base of the purine ring, all the other metabolites studied cleaved the glycosidic bond in the first fragmentation stage. Fragmentation was possible in the third to sixth stages. A liquid chromatography-high-resolution mass spectrometric method was developed and applied in the analysis of CRISPR-Cas9 genome-edited HeLa cells deficient in the individual enzymatic steps of PDNS and the salvage pathway. The identities of the newly synthesized intermediates of PDNS were confirmed by comparing the fragmentation patterns of the synthesized metabolites with those produced by cells (formed under pathological conditions of known and theoretically possible defects of PDNS). The use of stable isotope incorporation allowed the confirmation of fragmentation mechanisms and provided data for future fluxomic experiments. This method may find uses in the diagnosis of PDNS disorders, the investigation of purinosome formation, cancer research, enzyme inhibition studies, and other applications.

UI MeSH Term Description Entries
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072669 Gene Editing Genetic engineering or molecular biology techniques that involve DNA REPAIR mechanisms for incorporating site-specific modifications into a cell's genome. Base Editing,Genome Editing,Editing, Base,Editing, Gene,Editing, Genome
D012313 RNA A polynucleotide consisting essentially of chains with a repeating backbone of phosphate and ribose units to which nitrogenous bases are attached. RNA is unique among biological macromolecules in that it can encode genetic information, serve as an abundant structural component of cells, and also possesses catalytic activity. (Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) RNA, Non-Polyadenylated,Ribonucleic Acid,Gene Products, RNA,Non-Polyadenylated RNA,Acid, Ribonucleic,Non Polyadenylated RNA,RNA Gene Products,RNA, Non Polyadenylated
D053719 Tandem Mass Spectrometry A mass spectrometry technique using two (MS/MS) or more mass analyzers. With two in tandem, the precursor ions are mass-selected by a first mass analyzer, and focused into a collision region where they are then fragmented into product ions which are then characterized by a second mass analyzer. A variety of techniques are used to separate the compounds, ionize them, and introduce them to the first mass analyzer. For example, for in GC-MS/MS, GAS CHROMATOGRAPHY-MASS SPECTROMETRY is involved in separating relatively small compounds by GAS CHROMATOGRAPHY prior to injecting them into an ionization chamber for the mass selection. Mass Spectrometry-Mass Spectrometry,Mass Spectrometry Mass Spectrometry,Mass Spectrometry, Tandem
D064113 CRISPR-Cas Systems Adaptive antiviral defense mechanisms, in archaea and bacteria, based on DNA repeat arrays called CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS (CRISPR elements) that function in conjunction with CRISPR-ASSOCIATED PROTEINS (Cas proteins). Several types have been distinguished, including Type I, Type II, and Type III, based on signature motifs of CRISPR-ASSOCIATED PROTEINS. CRISPR Cas Systems,CRISPR-Cas System,System, CRISPR-Cas,Systems, CRISPR-Cas

Related Publications

Lucie Mádrová, and Matyáš Krijt, and Veronika Barešová, and Jan Václavík, and David Friedecký, and Dana Dobešová, and Olga Součková, and Václava Škopová, and Tomáš Adam, and Marie Zikánová
January 2006, Nucleosides, nucleotides & nucleic acids,
Lucie Mádrová, and Matyáš Krijt, and Veronika Barešová, and Jan Václavík, and David Friedecký, and Dana Dobešová, and Olga Součková, and Václava Škopová, and Tomáš Adam, and Marie Zikánová
February 2021, Critical reviews in biochemistry and molecular biology,
Lucie Mádrová, and Matyáš Krijt, and Veronika Barešová, and Jan Václavík, and David Friedecký, and Dana Dobešová, and Olga Součková, and Václava Škopová, and Tomáš Adam, and Marie Zikánová
January 1992, Progress in nucleic acid research and molecular biology,
Lucie Mádrová, and Matyáš Krijt, and Veronika Barešová, and Jan Václavík, and David Friedecký, and Dana Dobešová, and Olga Součková, and Václava Škopová, and Tomáš Adam, and Marie Zikánová
November 1968, Cancer chemotherapy reports. Part 2,
Lucie Mádrová, and Matyáš Krijt, and Veronika Barešová, and Jan Václavík, and David Friedecký, and Dana Dobešová, and Olga Součková, and Václava Škopová, and Tomáš Adam, and Marie Zikánová
March 2015, The Journal of biological chemistry,
Lucie Mádrová, and Matyáš Krijt, and Veronika Barešová, and Jan Václavík, and David Friedecký, and Dana Dobešová, and Olga Součková, and Václava Škopová, and Tomáš Adam, and Marie Zikánová
March 2013, Molecular genetics and metabolism,
Lucie Mádrová, and Matyáš Krijt, and Veronika Barešová, and Jan Václavík, and David Friedecký, and Dana Dobešová, and Olga Součková, and Václava Škopová, and Tomáš Adam, and Marie Zikánová
September 1991, The Journal of biological chemistry,
Lucie Mádrová, and Matyáš Krijt, and Veronika Barešová, and Jan Václavík, and David Friedecký, and Dana Dobešová, and Olga Součková, and Václava Škopová, and Tomáš Adam, and Marie Zikánová
January 1977, Advances in experimental medicine and biology,
Lucie Mádrová, and Matyáš Krijt, and Veronika Barešová, and Jan Václavík, and David Friedecký, and Dana Dobešová, and Olga Součková, and Václava Škopová, and Tomáš Adam, and Marie Zikánová
December 1983, The Biochemical journal,
Lucie Mádrová, and Matyáš Krijt, and Veronika Barešová, and Jan Václavík, and David Friedecký, and Dana Dobešová, and Olga Součková, and Václava Škopová, and Tomáš Adam, and Marie Zikánová
June 1978, Clinical science and molecular medicine,
Copied contents to your clipboard!